PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy. However, PD-L1 density could be a better biomarker, primary results of the PIONeeR trial suggest.
The PIONeeR project aims to predict response and/or resistance to PD-(L)1 immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients through comprehensive agnostic multiparametric and longitudinal biomarkers assessment.
Eligible are patients with advanced/metastatic NSCLC with available archived tumour tissue. Patients were treated with either nivolumab, pembrolizumab, or atezolizumab alone (second-line) or combined with chemotherapy (first-line) according to current standards. All patients were systematically re-biopsied and blood-sampled at 6 weeks of treatment. At ESMO, preliminary results, based on 100 enrolled patients, were presented .
Of 100 patients, 33 progressed before the 6-week milestone, 35 progressed between 6 and 24 weeks, 10 progressed between 24 and 52 weeks, and 21 patients had not progressed. Baseline parameters positively associated with response were: a higher percentage PD-L1-positive cells, cytotoxic lymphocytes in the tumour, cytotoxic lymphocytes at the tumour-stroma interface, and a higher percentage regulatory T cells in the stroma. Response was also associated with a higher percentage neutrophils in the tumour at 6 weeks. Both progression-free (PFS) and overall survival (OS) were strongly positively correlated with PD-L1-positive cell density in the tumour and/or stroma: PD-L1-positive cell density ≥22 cells/mm2 was correlated with improved PFS (P=0.014), whereas PD-L1 positive cell density ≥546 cells/mm2 was correlated with improved OS (P=0.015).
- Barlesi F, et al. Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study. ESMO 2020 Virtual Meeting, abstract LBA53.
« Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression Next Article
First-line immune checkpoint inhibition in metastatic NSCLC »
Table of Contents: ESMO 2020
Letter from the Editor
ESMO 2020 Highlights Podcast
COVID-19 and Cancer
Bladder cancer risk and early detection
Letter from the Editor
Adjuvant immune checkpoint inhibition after complete resection
First-line immune-combination therapies in mUC